How Celgene Hopes to Cash In on CAR-T – Madison.com
Madison.com |
How Celgene Hopes to Cash In on CAR–T
Madison.com Chimeric antigen T–cell therapy (CAR-T) is an important new approach to battling blood cancer, and while it's too soon to say what company will develop an approved treatment first, Celgene (NASDAQ: CELG) has a good shot at coming out on top. In January … |
